Comparison

ELISA Kit for Programmed Cell Death Protein 1 Ligand 1 (PDL1)

Item no. SEA788Hu-48T
Manufacturer Cloud-Clone
Amount 48 Tests
Quantity options 10x96 Tests 24 Tests 48 Tests 5x96 Tests 96 Tests
Category
Type Elisa-Kit
Specific against Human (Homo sapiens)
Sensitivity The minimum detectable dose of this kit is typically less than 0.056ng/mL
Citations Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications
High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial.
PD‐L1 gene polymorphisms and low serum level of PD‐L1 protein are associated to type 1 diabetes in Chile
Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study
High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis.
Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer
PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma
High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.
Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predictssurvival in advanced biliary tract cancer patients treated with palliative chemotherapy.
High post-treatment serum levels of soluble programmed cell death ligand 1 predict earlyrelapse and poor prognosis in extranodal NK/T cell lymphoma patients.
Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma
Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy.
Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients
Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy.
Inverse correlation of soluble programmed cell death-1 ligand-1 (sPD-L1) with eosinophil count and clinical severity in allergic rhinitis patients
Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy
Soluble Programed Death Receptor 1 Ligand (sPD-L1) in Pleural Fluid of Patients with Malignant Pleural Mesothelioma (MPM)
Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer
Increased levels of soluble programmed death ligand 1 associate with malignancy in patients with dermatomyositis
High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma
Increased levels of soluble co-stimulatory molecule PD-L1 (B7-H1) in the plasma of viraemic HIV-1+ individuals
Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma
Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between …
Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated …
Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer
Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer
The Clinical Significance of Soluble PD-1 and PD-L1 in Lung Cancer
Clinical implications of APOBEC3A and 3B expression in patients with breast cancer
Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study
Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma
The prognostic role of soluble transforming growth factor‐β and its correlation with soluble programmed death‐ligand 1 in biliary tract cancer
Prognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colorectal cancer patients
Soluble PD-L1: a potential immune marker for HIV-1 infection and virological failure
The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte
Prognostic prospect of soluble programmed cell death ligand-1 (sPD-L1) in cancer management
Microglial PD‐1 stimulation by astrocytic PD‐L1 suppresses neuroinflammation and Alzheimer's disease pathology
A Novel Small Cyclic Peptide-Based 68Ga-Radiotracer for Positron Emission Tomography Imaging of PD-L1 Expression in Tumors
Assessment of the RANTES Level Correlation and Selected Inflammatory and Pro-Angiogenic Molecules Evaluation of Their Influence on CRC Clinical Features: A …
ECLASS 10.1 32160605
ECLASS 11.0 32160605
UNSPSC 41116126
Alias CD274,PDCD1LG1,B7-H,B7H1,PD-L1,PDCD1L1,PDCD1-LG1,Programed Death Ligand 1
Available
Specificity Homo sapiens (Human)
Manufacturer - Applications
Enzyme-linked immunosorbent assay for Antigen Detection.
Manufacturer - Category
ELISA CLIA Kits
Sample type
Serum, plasma, tissue homogenates and other biological fluids
Assay length
3h
Method
Double-antibody Sandwich
Specificity

This assay has high sensitivity and excellent specificity for detection of Programmed Cell Death Protein 1 Ligand 1 (PDL1).

No significant cross-reactivity or interference between Programmed Cell Death Protein 1 Ligand 1 (PDL1) and analogues was observed.

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Programmed Cell Death Protein 1 Ligand 1 (PDL1) were tested 20 times on one plate, respectively.

Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Programmed Cell Death Protein 1 Ligand 1 (PDL1) were tested on 3 different plates, 8 replicates in each plate.

CV(%) = SD/meanX100

Intra-Assay: CV<10%

Inter-Assay: CV<12%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.

To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Assay procedure summary
1. Prepare all reagents, samples and standards;

2. Add 100uL standard or sample to each well. Incubate 2 hours at 37° C;

3. Aspirate and add 100uL prepared Detection Reagent A. Incubate 1 hour at 37° C;

4. Aspirate and wash 3 times;

5. Add 100uL prepared Detection Reagent B. Incubate 30 minutes at 37° C;

6. Aspirate and wash 5 times;

7. Add 90uL Substrate Solution. Incubate 10-20 minutes at 37° C;

8. Add 50uL Stop Solution. Read at 450nm immediately.
Test principle
The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Programmed Cell Death Protein 1 Ligand 1 (PDL1). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Programmed Cell Death Protein 1 Ligand 1 (PDL1). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Programmed Cell Death Protein 1 Ligand 1 (PDL1), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Programmed Cell Death Protein 1 Ligand 1 (PDL1) in the samples is then determined by comparing the O.D. of the samples to the standard curve.
Manufacturer - Research Area
Signal transduction; Tumor immunity; Infection immunity; Immune molecule; Autoimmunity;

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 48 Tests
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close